Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology

被引:47
作者
Goel, Raghuveera Kumar [1 ]
Lukong, Kiven Erique [1 ]
机构
[1] Univ Saskatchewan, Dept Biochem, 107 Wiggins Rd,Hlth Sci Bldg, Saskatoon, SK S7N 5E5, Canada
基金
加拿大健康研究院;
关键词
FRK; Rak; PTK5; SRMS; BRK; Src; Breast cancer; Tyrosine kinase; Tumour suppressor; Oncogene; BFKs; Fyn; PTEN; PROTEIN-TYROSINE KINASE; HUMAN GLIOMA-CELLS; BREAST-CANCER; RETINOBLASTOMA PROTEIN; LUNG-CANCER; COPY NUMBER; CONSTITUTIVE ACTIVATION; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; PLASMA-MEMBRANE;
D O I
10.1007/s10555-016-9623-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The non-receptor tyrosine kinase Fyn-related kinase (FRK) is a member of the BRK family kinases (BFKs) and is distantly related to the Src family kinases (SFKs). FRK was first discovered in 1993, and studies pursued thereafter attributed a potential tumour-suppressive function to the enzyme. In recent years, however, further functional characterization of the tyrosine kinase in diverse cancer types suggests that FRK may potentially play an oncogenic role as well. Specifically, while ectopic expression of FRK suppresses cell proliferation and migration in breast and brain cancers, knockdown or catalytic inhibition of FRK suppresses these cellular processes in pancreatic and liver cancer. Such functional paradox is therefore evidently exhibited in a tissue-specific context. This review sheds light on the recent developments emerged from investigations on FRK which include: (a) a review of the expression pattern of the protein in mammalian cells/tissues, (b) underlying genomic perturbations and (c) a mechanistic function of the enzyme across different cellular environments. Given its functional heterogeneity observed across different cancers, we also discuss the therapeutic significance of FRK.
引用
收藏
页码:179 / 199
页数:21
相关论文
共 95 条
[11]  
BECHER R, 1983, CANCER RES, V43, P5010
[12]   PATIENT WITH 13 CHROMOSOME DELETION - EVIDENCE THAT THE RETINOBLASTOMA GENE IS A RECESSIVE CANCER GENE [J].
BENEDICT, WF ;
MURPHREE, AL ;
BANERJEE, A ;
SPINA, CA ;
SPARKES, MC ;
SPARKES, RS .
SCIENCE, 1983, 219 (4587) :973-975
[13]  
Berclaz G, 2000, INT J CANCER, V85, P889
[14]   Cdk2 and Cdk4 cooperatively control the expression of Cdc2 [J].
Berthet, Cyril ;
Kaldis, Philipp .
CELL DIVISION, 2006, 1 (1)
[15]   EGFR gene amplification in breast cancer:: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations [J].
Bhargava, R ;
Gerald, WL ;
Li, AR ;
Pan, QL ;
Lal, P ;
Ladanyi, M ;
Chen, BY .
MODERN PATHOLOGY, 2005, 18 (08) :1027-1033
[16]   Clinical Considerations of BRCA1-and BRCA2-Mutation Carriers: A Review [J].
Bougie, O. ;
Weberpals, J. I. .
INTERNATIONAL JOURNAL OF SURGICAL ONCOLOGY, 2011, 2011
[17]   Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells [J].
Brauer, Patrick M. ;
Zheng, Yu ;
Wang, Lin ;
Tyner, Angela L. .
CELL CYCLE, 2010, 9 (20) :4190-4199
[18]   Building a better understanding of the intracellular tyrosine kinase FrTK6-BRK by BRK [J].
Brauer, Patrick M. ;
Tyner, Angela L. .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2010, 1806 (01) :66-73
[19]   RAKing in AKT A tumor suppressor function for the intracellular tyrosine kinase FRK [J].
Brauer, Patrick M. ;
Tyner, Angela L. .
CELL CYCLE, 2009, 8 (17) :2728-2732
[20]   N-cadherin expression level modulates integrin-mediated polarity and strongly impacts on the speed and directionality of glial cell migration [J].
Camand, Emeline ;
Peglion, Florent ;
Osmani, Nael ;
Sanson, Marc ;
Etienne-Manneville, Sandrine .
JOURNAL OF CELL SCIENCE, 2012, 125 (04) :844-857